Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm "ASCOT - LLA"


Phase N/A Results

Trial Description

To compare the long-term benefits of lowering cholesterol in hypertensive patients for the prevention of coronary heart disease and stroke.


  • Atorvastatin (LipitorĀ®)Drug
    Other Names: Lipitor
    Intervention Desc: Competitive inhibitor of HMG-CoA reductase; lowers cholesterol and lipids

Trial Design

Multicenter, double-blind randomized subset of the ASCOT trial.

Patient Involvement

Patients were randomly assigned to receive either 10mg atorvastatin (n=5168) or placebo (n=5137) daily.


Type Measure Time Frame Safety Issue
Primary Assess and compare the long-term effects of statin vs placebo on non-fatal myocardial infarction, silent myocardial infarction, and fatal coronary heart disease.
Secondary All causes of mortality, fatal and non-fatal stroke, fatal and non-fatal heart failure, total coronary endpoints, and total cardiovascular events.